Mesa Laboratories Inc: Form 10-Q for the period ended Sep 30, 2016
Filed with the SEC on Nov 7, 2016 and accepted by EDGAR at Nov 7, 2016, 08:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 6 months2016-04-01 to 2016-09-30 | $45.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-07-01 to 2016-09-30 | $10.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2016-04-01 to 2016-09-30 | $19.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2016-07-01 to 2016-09-30 | $13.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2016-04-01 to 2016-09-30 | $25.7m | us-gaap:GrossProfit |
| Research and development | 3 months2016-07-01 to 2016-09-30 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-04-01 to 2016-09-30 | $2.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-07-01 to 2016-09-30 | $4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-04-01 to 2016-09-30 | $6.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2016-07-01 to 2016-09-30 | $854.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2016-04-01 to 2016-09-30 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-07-01 to 2016-09-30 | $2.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2016-04-01 to 2016-09-30 | $4.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2016-07-01 to 2016-09-30 | $0.62 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2016-04-01 to 2016-09-30 | $1.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-07-01 to 2016-09-30 | $0.64 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2016-04-01 to 2016-09-30 | $1.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-07-01 to 2016-09-30 | 3,831,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2016-04-01 to 2016-09-30 | 3,816,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Dividends paid | 6 months2016-04-01 to 2016-09-30 | $1.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2016-09-30 | $5.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-09-30 | $34.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-09-30 | $166.3m | us-gaap:Assets |
| Current liabilities | At period end2016-09-30 | $21.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-09-30 | $76.0m | us-gaap:Liabilities |
| Long-term debt | At period end2016-09-30 | $49.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-09-30 | $3.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-09-30 | $90.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-16-041190. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.